To Assess Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine, When co-Administered With DTPa-Combined Vaccines and MenC or Hib-MenC Vaccines During the First 6 Months of Age.

Trial Profile

To Assess Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine, When co-Administered With DTPa-Combined Vaccines and MenC or Hib-MenC Vaccines During the First 6 Months of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hib-DTaP-hepatitis B-poliovirus vaccine; Hib-meningococcal vaccine group C conjugate; Meningococcal vaccine group C conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Pertussis; Pneumococcal infections; Poliomyelitis; Streptococcal infections; Tetanus
  • Focus Adverse reactions; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Mar 2011 Actual initiation date of the parent trial is Jun 2006 and actual end date is Jul 2007 as reported by ClinicalTrials.gov (NCT00334334).
    • 01 Apr 2009 Results published in The Pediatric Infectious Disease Journal.
    • 09 Oct 2008 Study start date changed from June to February 2006, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top